Vogenx posted a $384,430 net loss for the three months ended June 30, 2026, with no Revenue from product sales. The result matters to investors because the company had no products approved for commercial sale, held $193,017 in cash at quarter-end and later received approximately $84.9 million in IPO net proceeds.
Key Highlights
- Vogenx received approximately $84.9 million in net IPO proceeds in August 2026.
- Accumulated Deficit reached $11,701,552 at June 30, 2026.
- Cash and cash equivalents totaled $193,017 at June 30, 2026.
Vogenx, Inc. (NASDAQ: VOGX) posted a net loss of $384,430 for the three months ended June 30, 2026. The clinical-stage life science company generated no revenue from product sales during the quarter. Its activities remained focused on staffing and organisation, business planning, Capital raising and research and development.
Quarterly Loss And Earnings Per Share
Vogenx said it had no products approved for commercial sale, leaving product-sales revenue at zero for the period. Research and Development activities included nonclinical and clinical testing of mizagliflozin.
Mizagliflozin Development Focus
Mizagliflozin is being developed for post-bariatric hypoglycemia and gastroparesis. Vogenx described it as a selective SGLT1 inhibitor intended for disorders associated with glucose absorption and postprandial dysregulation. The company’s operations also covered business planning, capital raising and corporate staffing.
Cash And Current Liabilities
Cash and cash equivalents stood at $193,017 on June 30, 2026, compared with $601,010 on December 31, 2025. Deferred offering costs were $1,204,631, while prepaid expenses and other current Assets were $11,380. Total current assets were $1,409,028. Accounts Payable amounted to $1,223,671 and accrued expenses were $1,095,543. The Warrant Liability was $1,415, while convertible promissory notes payable to a related party were $867,700. Total current liabilities and total liabilities were each $3,188,329.
Capital Raised After Quarter-End
Vogenx completed its initial public offering in August 2026 and received approximately $84.9 million in net proceeds after Underwriting discounts, commissions and offering expenses. The company said its June 30 financial statements did not reflect the IPO because the transaction closed after the quarter ended. The company also stated that its operations had not generated product-sales revenue and that it expected no such revenue in the foreseeable future, if at all, while its product candidates remained in clinical and preclinical development.



Please wait processing your request...